Literature DB >> 9175031

Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus.

O De Pità, A M Bellucci, M Ruffelli, C R Girardelli, P Puddu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175031     DOI: 10.1177/096120339700600414

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


× No keyword cloud information.
  6 in total

Review 1.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 2.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

4.  Intravenous immunoglobulin in the management of lupus nephritis.

Authors:  Scott E Wenderfer; Trisha Thacker
Journal:  Autoimmune Dis       Date:  2012-09-27

5.  Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study.

Authors:  Christa Ky; Brian Swasdibutra; Shaadi Khademi; Sheetal Desai; Vivian Laquer; Sergei A Grando
Journal:  Dermatol Reports       Date:  2015-03-16

Review 6.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.